GI Partners completed the acquisition of Charles River Laboratories’ CDMO and Cell Solutions businesses and formed Rose BioSolutions as an independent platform focused on advanced therapy manufacturing. Rose Bio will provide development and manufacturing capabilities across plasmid DNA, viral vectors, cell therapy and cellular materials.

The platform is positioned to serve cell and gene therapy customers as a standalone business backed by GI Partners. GI Partners said Rose Bio was created to combine CDMO manufacturing capabilities with Cell Solutions’ cellular starting-materials capabilities in one focused organization.